MBX: MBX Biosciences, Inc. Common Stock

Price Chart

Key Statistics

Market Cap(EOD)494.33M

Enterprise Value455.20M

P/E Ratio (TTM)-6.39

P/B Ratio (TTM)2.24

P/S Ratio (TTM)2226.73

Earnings Yield (TTM)-15.65%

ROE (TTM)-31.33%

ROIC (TTM)-39.36%

Net Profit Margin (TTM)N/A

Dividend Yield (TTM)N/A

Payout Ratio (TTM)N/A

Debt/Equity (TTM)0.00

About MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.